HuidaGene Therapeutics, a global oncology-focused biotech company, has announced its first treatment in its multinational HG004 gene therapy study (STAR study). This phase 1/2a investigation uses CRISPR-influenced programmable genomic drugs to potentially treat inherited retinal dystrophies caused by RPE65 gene mutations.

Novartis reported FDA's approval of Cosentyx® (secukinumab) for the management of moderate to extreme hidradenitis suppurativa in adult patients.

The FDA has given its sanction for Wezlana (ustekinumab-auub), considering it a biosimilar and substitute for Stelara (ustekinumab) in treating several inflammatory conditions.

The U.S. Food and Drug Administration (FDA) has given permission to resume the Phase 1 clinical trial of XMT-2056, according to Mersana Therapeutics, Inc., a biopharmaceutical firm in the clinical stage.

Lirum Therapeutics announces encouraging results on LX-101, an innovative, clinical-phase targeted treatment, showing significant preliminary efficacy against children's sarcomas.

Context Therapeutics has revealed promising preclinical results for its research asset, CTIM-76.

Chimeric Therapeutics has disclosed that the US FDA has given the green light to the IND submission for CHM 2101.

AceLink Therapeutics announced the initiation of AL01211 dosage for the first patient in its Phase 2 study for Fabry disease in China.

Nimbus Therapeutics, LLC has now shared preliminary findings from its ongoing Phase 1/2 trial of NDI-101150, an HPK1 small-molecule inhibitor.

Immunology firm, INmune Bio, Inc. will present its findings on the use of INB03 in managing high-risk MUC4 expressing HER2+ breast cancer. INB03 is a dominant-negative suppressor of soluble TNF.

Sarepta Therapeutics, Inc. shared initial results from EMBARK, a global Phase 3 trial evaluating ELEVIDYS (delandistrogene moxeparvovec-rokl) in Duchenne muscular dystrophy patients aged 4-7.

SparX Biopharmaceutical Corp. happily announces FDA approval of its IND application for SPX-303, a key development in powered antibody therapies and a leading anti-LILRB2/PD-L1 bispecific antibody drug candidate.